Literature DB >> 29507458

Ixekizumab for psoriasis.

.   

Abstract

Entities:  

Year:  2017        PMID： 29507458      PMCID： PMC5828924          DOI： 10.18773/austprescr.2017.080

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  4 in total

Review 1.  Secukinumab.

Authors: 
Journal:  Aust Prescr       Date:  2015-11-19

2.  Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.

Authors:  Christopher E M Griffiths; Kristian Reich; Mark Lebwohl; Peter van de Kerkhof; Carle Paul; Alan Menter; Gregory S Cameron; Janelle Erickson; Lu Zhang; Roberta J Secrest; Susan Ball; Daniel K Braun; Olawale O Osuntokun; Michael P Heffernan; Brian J Nickoloff; Kim Papp
Journal:  Lancet       Date:  2015-06-10       Impact factor: 79.321

3.  Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.

Authors:  Peter Nash; Bruce Kirkham; Masato Okada; Proton Rahman; Benard Combe; Gerd-Ruediger Burmester; David H Adams; Lisa Kerr; Chin Lee; Catherine L Shuler; Mark Genovese
Journal:  Lancet       Date:  2017-05-24       Impact factor: 79.321

4.  Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

Authors:  Kenneth B Gordon; Andrew Blauvelt; Kim A Papp; Richard G Langley; Thomas Luger; Mamitaro Ohtsuki; Kristian Reich; David Amato; Susan G Ball; Daniel K Braun; Gregory S Cameron; Janelle Erickson; Robert J Konrad; Talia M Muram; Brian J Nickoloff; Olawale O Osuntokun; Roberta J Secrest; Fangyi Zhao; Lotus Mallbris; Craig L Leonardi
Journal:  N Engl J Med       Date:  2016-06-08       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.